Ojjaara Tablets Price and Access in India Through Named Patient Program
%20tablets%20price%20and%20availability%20in%20India.png)
Ojjaara (Momelotinib) 100 mg tablets available Online in India For patients living with intermediate or high-risk myelofibrosis accompanied by anemia, access to innovative therapies can significantly influence treatment outcomes. Ojjaara or Momelotinib , developed by GlaxoSmithKline (GSK), is one such advancement that has gained regulatory approvals in the United States and Europe for treating adults with myelofibrosis and anemia. The medication is specifically indicated for patients with primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. The FDA-approved prescribing information recommends a standard dosage of 200 mg once daily and confirms its availability in 100 mg, 150 mg and 200 mg tablet strengths. Despite its international approvals, many patients in India wonder about Ojjaara's availability locally and how they can legally obtain it. Understanding the regulatory process can help patients and caregivers access the me...